Condition
Pleural Mesothelioma|Peritoneal Mesothelioma
Estimated Enrollment: 40
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: NIBIT-MESO-1
Study First Received: October 26, 2015
Last Updated: October 26, 2015
Estimated Primary Completion Date: June 2016
Primary Outcome Measures:
immune-related (ir)- objective response rate (ORR)|Immune-related-Disease control rate (ir-DCR)|Disease control rate (DCR)|Immune-related-progression-free-survival (PFS)|progression-free-survival (PFS)|Overall survival (OS)|Safety (adverse events)|Immune-related-ORR based on PD-L1 tumor expression|Immune-related-Disease control rate based on PD-L1 tumor expression|Immune-related-progression- free-survival based on PD-L1 tumor expression|Overall survival based on PD-L1 tumor expression
Sponsors and Collaborators:
Italian Network for Tumor Biotherapy Foundation|AstraZeneca
Website Link: https://ClinicalTrials.gov/show/NCT02588131
